Yusuke Ushio
Overview
Explore the profile of Yusuke Ushio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ushio Y, Hirata S, Manabe S, Suyama M, Tanaka A, Seki M, et al.
BMC Nephrol
. 2025 Mar;
26(1):109.
PMID: 40033218
Background: Cyanotic nephropathy (CN) is a known complication of cyanotic congenital heart disease (CCHD). However, many aspects of its pathophysiology remain unclear. Case Presentation: We report the case of a...
2.
Sugihara K, Wakiya R, Kameda T, Shimada H, Nakashima S, Miyagi T, et al.
Sci Rep
. 2024 Dec;
14(1):30416.
PMID: 39639150
Arthritis is one of the most common symptoms of Behcet's Disease (BD) observed in 57% of Japanese patients with BD. The relationship between arthritis and other clinical symptoms of BD...
3.
Ushio Y, Yokoyama T, Manabe S, Seki M, Kawaguchi Y, Kobayashi S, et al.
Kidney Int
. 2024 Oct;
106(5):999.
PMID: 39428178
No abstract available.
4.
Nitta K, Kataoka H, Manabe S, Makabe S, Akihisa T, Ushio Y, et al.
Clin Exp Nephrol
. 2024 Sep;
29(1):75-82.
PMID: 39322826
Background: Serum phosphate (P) levels are generally lower in autosomal dominant polycystic kidney disease (ADPKD) than in other kidney disorders, potentially masking the clinical significance of hyperphosphatemia. This study aimed...
5.
Mochida H, Kyoda M, Ushio Y, Morito T, Kamiyama T, Oyagi H, et al.
CEN Case Rep
. 2024 Jun;
14(1):53-60.
PMID: 38918330
Crystalglobulin-induced nephropathy is a rare disease that causes the deposition of crystallized monoclonal immunoglobulins into the glomerular capillary and arteriole spaces. Here, we report the case of a patient who...
6.
Ushio Y, Wakiya R, Kameda T, Nakashima S, Shimada H, Miyagi T, et al.
BMC Rheumatol
. 2024 Jun;
8(1):27.
PMID: 38886779
Background: In 2020, Nintedanib (NTB), a tyrosine kinase inhibitor, was the first drug approved worldwide for treating progressive fibrosing interstitial lung disease (PF-ILD). This study evaluated the efficacy and safety...
7.
Nakatani S, Kawano H, Sato M, Hoshino J, Nishio S, Miura K, et al.
Clin Exp Nephrol
. 2024 May;
28(10):1004-1015.
PMID: 38734869
Background: Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are major genetic polycystic kidney diseases that can progress to end-stage kidney disease (ESKD). Longitudinal data...
8.
Ushio Y, Akihisa T, Karasawa K, Seki M, Kobayashi S, Miyabe Y, et al.
BMC Nephrol
. 2024 Feb;
25(1):66.
PMID: 38395839
Background: IgG4-related disease (IgG4-RD) is a fibroinflammatory disease that affects multiple organs, including the pancreas, lacrimal glands, salivary glands, periaortic/retroperitoneum, and kidney. Interstitial nephritis is a typical renal disorder associated...
9.
Ushio Y, Kataoka H, Akagawa H, Sato M, Manabe S, Kawachi K, et al.
J Nephrol
. 2024 Feb;
37(4):983-992.
PMID: 38315279
Background: Recently, the importance of attribute-based medicine has been emphasized. The effects of early-onset intracranial aneurysms on patients can be significant and long-lasting. Herein, we compared the factors associated with...
10.
Akihisa T, Kataoka H, Makabe S, Manabe S, Yoshida R, Ushio Y, et al.
Nephrol Dial Transplant
. 2023 Nov;
39(6):1008-1015.
PMID: 37935473
Background: Tolvaptan, a vasopressin V2 receptor antagonist, is used for treating autosomal dominant polycystic kidney disease (ADPKD). We focused on changes in urinary osmolality (U-Osm) after tolvaptan initiation to determine...